Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $55.38.

KYMR has been the topic of a number of recent research reports. Oppenheimer increased their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. UBS Group cut their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Finally, BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective on the stock.

Kymera Therapeutics Price Performance

KYMR stock opened at $40.89 on Friday. The firm has a 50 day simple moving average of $44.96 and a two-hundred day simple moving average of $43.59. The stock has a market cap of $2.65 billion, a PE ratio of -17.47 and a beta of 2.16. Kymera Therapeutics has a one year low of $22.35 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period in the previous year, the business earned ($0.90) earnings per share. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. On average, research analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after acquiring an additional 915 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $61,000. Arizona State Retirement System boosted its holdings in Kymera Therapeutics by 15.6% in the second quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after acquiring an additional 1,730 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its position in shares of Kymera Therapeutics by 12.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock worth $819,000 after purchasing an additional 1,900 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.